Navigation Links
DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation
Date:6/29/2009

ryptogenic organizing pneumonia, as compared to none of the orBec(R)-treated patients (p = 0.04).

The investigators, led by Dr. Jason Chien, reviewed data from two previous randomized, double-blind, placebo-controlled Phase 2 and 3 clinical trials evaluating orBec(R), for the treatment of acute GI GVHD. Data from 120 patients (sixty patients treated with orBec(R), sixty placebo) were available for this retrospective analysis. Patients were enrolled in these studies at the Fred Hutchinson Cancer Research Center, where pulmonary function testing is done prospectively and all patients with pulmonary complications are evaluated with a standard protocol. The investigators also evaluated adverse event reports of infectious and non-infectious inflammation of the lung.

These observations by Dr. Chien and colleagues on the preservation of pulmonary function among patients receiving orBec(R) is consistent with findings from the Phase 3 randomized trial reported by Hockenbery et al. (A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease. Blood 109: 4557 - 4563, 2007).

"While these trials were not designed to look at pulmonary endpoints, these observations suggest that a metabolite of oral BDP may be having a beneficial anti-inflammatory effect in the lungs of hematopoietic cell transplant recipients," stated Jason W. Chien, MD, MS, Assistant Member, Clinical Research Division of the Fred Hutchinson Cancer Research Center. "There was convincing evidence of preservation of lung function and an absence of non-infectious pulmonary disease in those who had received oral BDP. The explanation for this benefit appears to be related to the delivery of a small amount of the potent metabolite, 17-beclomethasone monopropionate, from the intestinal mucosa to the pulmonary artery via the p
'/>"/>

SOURCE DOR BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
2. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
3. PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty
4. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
5. PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development
6. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
7. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
8. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
9. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
10. Morria Biopharmaceuticals Plc Announces Appointment of Dr. Rosemary Mazanet as Interim Chief Executive Officer
11. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... 2015 HUYA Bioscience International (HUYA) today announced the ... Society of HTLV-1, held this week at the University ... the Society is to promote research on HTLV-1 and ... technology and research related to these fields to advance ... is proud to support this prestigious conference," said ...
(Date:8/27/2015)... RESEARCH TRIANGLE PARK, N.C. , Aug. 27, ... reports on the decision by FedEx, UPS and ... shipments of certain biological specimens classified as ,select ... expertise and long history of handling these sensitive ... network, knowledge of global transportation regulations, trained and ...
(Date:8/26/2015)... WARREN, N.J. , Aug. 26, 2015  Roka ... company focused on providing advanced testing solutions for the ... Thomas, CEO will present at the Sidoti & Company ... The conference will be held at the New York ... the presentation will be available through the investor relations ...
(Date:8/26/2015)... GERMANTOWN, Md. , Aug. 26, 2015 ... synthetic biology, announced today the closing of its previously ... in full by the underwriters of their option to ... the public offering price of $41.00 per share.  The ... of shares of common stock sold by Intrexon to ...
Breaking Biology Technology:HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 3HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 4Marken Ensures Safe Transportation Of Select Agents And Toxins 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 4
... Support for National Children,s Program, OJAI, Calif., ... Officer of Tishcon Corp and visionary philanthropist easily,recognized ... income children in,America. In January 2000, Raj Chopra, ... Vice President, Arun Chopra, initiated a,monthly donation to ...
... 2:00 p.m. PT ... (5:00 p.m. ET), IRVINE, ... Pulse CO-Oximetry and,Measure-Through-Motion- and-Low-Perfusion pulse oximetry, today announced,it will release third quarter ... on Monday, October 27, 2008., A conference call to review the ...
... 15 PURE Bioscience (Nasdaq:,PURE), creators of the ... for the fiscal year ended July 31, 2008 ... $336,400 in the,prior fiscal year. The Company reported ... $(0.24) per share, compared with a loss of,$(4,654,900), ...
Cached Biology Technology:Tishcon Corp Reaches Donation Milestone Exceeds 1 Million Bottles of Multi-Vitamins for Nourish America 2Tishcon Corp Reaches Donation Milestone Exceeds 1 Million Bottles of Multi-Vitamins for Nourish America 3Masimo to Report Third Quarter 2008 Financial Results on October 27, 2008 2PURE Bioscience Reports Fourth Quarter and Year End Results 2PURE Bioscience Reports Fourth Quarter and Year End Results 3PURE Bioscience Reports Fourth Quarter and Year End Results 4PURE Bioscience Reports Fourth Quarter and Year End Results 5PURE Bioscience Reports Fourth Quarter and Year End Results 6PURE Bioscience Reports Fourth Quarter and Year End Results 7
(Date:8/12/2015)... Calif. , Aug. 12, 2015  Synaptics ... of human interface solutions, today announced that four ... announced Match-in-Sensor solution, have officially been named FIDO ... As part of the certification, Synaptics, Natural ID™ ... 1.0 Universal Authentication Framework (UAF) standard and are ...
(Date:8/6/2015)... , Aug. 6, 2015  Today, U.S. ... visit Crossmatch ™ to learn firsthand how ... protect data. Crossmatch is a world leader in ... and expertise are helping federal agencies and commercial ... security.   "The vast majority of ...
(Date:8/5/2015)... Transparency Market Research has released ... Global Industry Analysis, Size, Share, Growth, Trends and Forecast ... is forecast to reach US$ 2,671.8 Mn by 2022. ... systems by civil and government agencies. This is majorly ... activities across the globe that would elevate the demand ...
Breaking Biology News(10 mins):Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3Rep. Honda to Visit Crossmatch in Redwood City 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6
... - Eurofins MWG Operon, an expert in next generation sequencing ... libraries for sequencing with Roche GS FLX or Illumina HiSeq ... long paired end (LPE) libraries with different jumping distances (3 ... After sequencing, the resulting reads are assembled into large contigs ...
... of a TB Vaccine PDP, An Exhibitor,s Workshop at the ... 1:00-2:00 PM VENUE: 2011 AAAS ANNUAL MEETING, ,WASHINGTON CONVENTION ... an overview of the state of the global TB epidemic ... product development partnerships such as Aeras; and ways that scientists ...
... found attached to the foot of an ancient Egyptian mummy ... parts, says the scientist who tested replicas on volunteers. ... a three-part wood and leather artefact housed in the Egyptian ... Chester artificial toe on display in the British Museum, not ...
Cached Biology News:Mummies' false toes helped ancient Egyptians walk 2
... filters allow for the rapid isolation of DNA ... gel slice in the spin filter, centrifuge for ... is recovered. There is no need to melt ... filters can also be used for buffer exchange, ...
ChemiArray Human Cytokine Antibody Array VII, 60 cytokines per membrane...
Request Info...
...
Biology Products: